International Urology and Nephrology

, Volume 36, Issue 4, pp 591–598 | Cite as

Oral supplement of six selective amino acids arrest progression renal failure in uremic patients

Article

Abstract

Certain amino acids such as glycine, L-aspartic acid, L-glutamic acid, L-glutamine, L-histidine and L-arginine taken orally by normal adults or patients with renal failure increase glomerular filtration rate (GFR). Twelve nondiabetic patients suffering from glomerulonephritis confirmed by renal biopsy previously, with creatinine clearances ranging from 15 to 24 ml minute/1.73, and on low protein diet 0.6 g/kg/day, received an amino acid supplement daily in 2 or 3 doses for 1 year. At 4, 8 and 12 months creatinine clearance increased slightly (NS, NS, NS), 24 hour urine volume increased (P ≤ 0.001, 001, 0.001), 24 hour albuminuria decreased (P<0.001, 0.001, 0.001), serum urea increased (NS, NS, NS) serum albumin increased (NS, 0.05, 0.05), total cholesterol decreased slightly (NS, NS, 0.01), HDL increased slightly (0.05, 0.05, 0.05), LDL decreased (NS, 0.001, 0.001) triglycerides decreased (0.001, 0.001, 0.001), Apo B remained unchanged (NS, NS, NS), ROS/H2O2 decreased (0.001, 0,001, 0.001), Hct increased (NS, 0.01, 0.01) Hb increased (0.05, 0.05, 0.05) and serum phosphate decreased (0.01, 0.01, 0.01). After removal of supplements at the end of the year all parameters remained unchanged. We believe that a large controlled study should be undertaken to confirm these most encouraging findings.

Keywords

Chronic kidney disease Glycine Essential amino acids L-Arginine L-Aspartic acid L-Glutamine L-Glutamine acid Prevention of renal disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Modification of Diet in Renal Disease (MDRD) study group (prepared by Beck GJ, Beck RL, Coggins CH, Gassman JJ, Hunsicker LG, Schluter MD, Williams GW). Design and studistical issues of the Modication of Diet in Renal Disease Trial. Controlled Clin Trials 1991; 12: 566–586.Google Scholar
  2. Levey, AS, Greene, T, Schluchter, MD,  et al. 1993The modification of diet in renal disease (mdrd) study and the diabetes control and complications trial (dcct) research group: glomerular filtration rate measurement in clinical trials.J Am Soc Nephrol311591171Google Scholar
  3. Modification of Diet in Renal Disease (MDRD) study group (prepared by Greene T, Bourgoignie JJ, Habwe VQ, Kusec JW, Snetsellaar L, Soucie JM, Yamamoto M). Baseline characteristics in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1993; 3: 1819–1834 (original version); 1993; 4: 1221–1236 (corrected version).Google Scholar
  4. Klahr, S, Levey, AS, Berk, GJ,  et al. 1994The modification of diet in renal disease (MDRD) Study Group.The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med330877884Google Scholar
  5. Peterson, J, Adler, S, Burkart, J,  et al. 1995For The modification of diet in renal disease (MDRD) study group.Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Annal Intern Med123754762Google Scholar
  6. The Modification of Diet in Renal Disease (MDRD) Study GroupKlahr, S, Breyer, JA, Beck, GJ, Dennis, VW, Hartman, JA, Roth, D, Steinman, TI, Wang, S-R, Yamamoto, ME 1995Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease.J Am Soc Nephrol520372047Google Scholar
  7. Levey, A, Adler, S, Caggiula, A,  et al. 1996For The MDRD Study Group.Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis27652663Google Scholar
  8. The Modification of Diet in Renal Disease (MDRD) Study GroupHunsicker, LG, Adler, S, Caggiula, A, England, BK, Green, T, Kusek, JW, Rogers, NL, Teschan, PE 1997Predictors of the progression of renal disease in the modification of diet in renal disease study.Kidney Int5119081919Google Scholar
  9. Lazarus, JM, Bourcoignie, JJ, Buckalew, VM,  et al. 1997For the Modification of Diet in Renal Disease Study Group.Achievement of safety of a low blood pressure goal in chronic renal disease in the Modification of Diet in Renal Disease Study. Hypertension29641650Google Scholar
  10. Klahr, S 1997Prevention of progression of nephropathy.Nephrol Dial Transplant126366(Suppl 2)Google Scholar
  11. Hebert, La, Kusek, Jw, Greene, T,  et al. 1997Effects of blood pressure control on progressive renal disease in blacks and whites.Modification of Diet in Renal Disease Study Group. Hypertension30428435Google Scholar
  12. Wanner, C, Greiber, S, Kramer-Guth, A,  et al. 1997Lipid and progression of renal disease: role of modified low density lipoprotein and lipoprotein (A).Kidney Int52S-102S-106Suppl 63Google Scholar
  13. Eddy, Aa, Liu, E, Me Culloch,  L 1998Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades.Kidney Int5311821189Google Scholar
  14. Keane, Wf 2000The role of lipid in renal disease: future challenges.Kidney Int57S-27S-31Suppl 75Google Scholar
  15. Campese, Vm, Romoff, Ms, Levitan, D, Massry, Sg 1981Mechanisms of autonomic nervous system dysfunction in uremia.Kidney Int20246253Google Scholar
  16. Izzo, Zl, Izzo, Ms, Sterns, Rh, Freeman, Rb 1982Sympathetic nervous system-hyperactivity in maintenance hemodialysis patients.Trans Am Soc Artif Organs28604606Google Scholar
  17. Katholi, Re, Whitlow Pl Hageman, Gr, Woods, T 1984Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves.J Hypertension2349359Google Scholar
  18. Converce, Rl, Jacobsen, Tn, Toto, Rd,  et al. 1992Sympathetic overactivity in patients with chronic renal failure.N Engl J Med32719121918Google Scholar
  19. Campese, Vm, Kogosov, E, Koss, M 1995Renal afferent denervation prevents the progression of renal disease ablation model of chronic renal failure in the rat.Am J Kidney Dis26861865Google Scholar
  20. Herzog, Ca, Ma, Jz, Collins, Aj 1998Poor long-term surival after acute myocardial infarction among patients on long-term dialysis.N Engl J Med339799805CrossRefPubMedGoogle Scholar
  21. Cambese, Vm 2000Neurogenic factors and hypertension in renal disease.Kidney Int57S-2S-6Suppl 75Google Scholar
  22. Rump, Lc, Amann, K, Orth, S, Ritz, E 2000Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uremia?Nephrol Dial Transplant1517351738Google Scholar
  23. Ibrahim, Hn, Rosenberg, Me, Greene, El,  et al. 1997Aldosterone is a major factor in the progression of renal disease.Kidney Int52S-115S-l19Suppl 63Google Scholar
  24. Klahr, S, Morrissey, Jj 2000The role of vasoactive compounds, growth factors and citokines in the progression of renal disease.Kidney Int57S-7S-14Suppl 75Google Scholar
  25. Fogo, A. 2000Glomerular hypertension, abnormal glomerular growth, and progression of renal diseasesKidney Int57S-15S-21Suppl 75Google Scholar
  26. D’Amico, G 1999Tubulointerstitium as predictor of progression of glomerular disease.Nephron83289295CrossRefPubMedGoogle Scholar
  27. Ter Wee, Pm, Donker, Ajm 1992Clinical strategies for arresting progression of renal diseaseKidney Int42S-114S-120Suppl 38Google Scholar
  28. Tarif, N, Bakris, Gl 1997Preservation of renal function: the spectrum of effects by calcium-channel blockers.Nephrol Dial Transplant1222442250Google Scholar
  29. Romero, F, Rodriguez-Iturbe, B, Parra, G,  et al. 1999Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.Kidney Int55945955Google Scholar
  30. Barsotti, G, Cupisti, A, Gervasi, Gb,  et al. 1999Effects floral administration of heparan sulfate in the rat remmant kidney model.Nephron81310318Google Scholar
  31. Miller, Sb, Martin, Dr, Kissane, J, Hammrman, Mr. 1994Hepatocyte growth factor accelerate recovery from acute ischemic renal injury in rat.Am J Physiol35F 129F 134Renal fluid electrolyte physiolGoogle Scholar
  32. Liu, Y, Tolber, Em, Lin, L,  et al. 1999Up-regulation of hepatocyte growth factor receptor: amplication and targeting mecanisms for hepatocyte growth factor action in acute renal failure.Kidney Int55442453Google Scholar
  33. Liu, Y, Rajur, K, Tolber, E, Drorkin, Ld 2000Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways.Kidney Int5820282043Google Scholar
  34. Matsumoto, K, Nakamura, T 2001Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases.Kidney Iit5920232038Google Scholar
  35. Breeders, N, Knoop, C, Antoine, M,  et al. 2000Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only inncuous agent?Nephrol Dial Transplant1519931999Google Scholar
  36. Chapman, Ab, Gabow, Pa, Schrier, Pm 1991Reversible renal failure associated with angiotensine-converting-enzyme inhibitors in polycystic kidney diseaseAnn Int Med115769773Google Scholar
  37. Devoy, Ma, Tomson, Cr, Edmunds, Me,  et al. 1992Deterioration in renal function associated with angiotensive converting enzyme inhibitor therapy is not always reversible.J Intern Med232493498Google Scholar
  38. Akone, D, Cante, D, Cillo, F,  et al. 1996Blood pressure and progression of failure in the elderly.Kidney Lit49S75S77Suppl 55Google Scholar
  39. Essen,  Gg, Rensma, P1, De Zeeuw,  D,  et al. 1996Association between angiotensine-converting-enzyme gene polymorphism and failure of renoprotective therapy.Lancet3479495Google Scholar
  40. Tanner, Ga 1998Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease.J Am Soc Nephrol912421248Google Scholar
  41. Tanner, Ga, Tanner, Ja 2000Citrate therapy for polycystic kidney disease in rats.Kidney Int5818591869Google Scholar
  42. Katholi, Re, Winternitz, Sr, Oraril, S 1982Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat.J Clin Invest695562Google Scholar
  43. Fellstrom, B, Backman, U, Larsson, E, Zezina, L 1993Immunologic and nonimmunologic factors of chronic rejection.Transplant Proc3113041305Google Scholar
  44. Remuzzi, G, Ruggenenti, B, Benigni, A 1997Understanding the nature of renal disease progression.Kidney Int51215PubMedGoogle Scholar
  45. Remuzzi, G, Perico, N 1998Protecting single-kidney allografts from long-term functional Deterioration.J Am Soc Nephrol913211332Google Scholar
  46. Ponticelli, C 2000Progression of renal damage in chronic rejectionKidney Int57S-62S-70Suppl 75Google Scholar
  47. Ritz,  E, Schomic, M, Wagner, J 2000ounteracting progression of renal disease: A look into the futureC. Kidney Int57S-71S-76Suppl 75Google Scholar
  48. Ojo, Ad, Hanson, Ja, Wolfe, Ra,  et al. 2000Long-term survival in renal transplant recipients with graft function.Kidney Int57307313Google Scholar
  49. Solez K And 27 Other Investigators1993International standardization of criteria for the histologic diagnosis of renal allograft rejection.The Banff workin classification of kidney transplant pathology. Kidney Int44411422Google Scholar
  50. Wright, Jr, Duggal, Ad, Thomas, R,  et al. 2001Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic removascular disease.Nephrol Dial Transphant16765770Google Scholar
  51. Laidlaw, Sa, Kopple, Jd 1987Newer concepts of the indispensable amino acids.Am J Clin Nutr46593605Google Scholar
  52. Yatzidis, H, Dombros, Nv, Digenis, Ge 1996On the usefulness of glycylglycine in hemodialysis and peritoneal dialysis solutions.ASAIO J42984992Google Scholar
  53. Newberger, A 1981The metabolism of glycine and serine.Comprehensive Biochem19(A)257303Google Scholar
  54. Jackson, Aa 1991The glycine story.Eur J Clin Nutr455965Google Scholar
  55. Pitts, R 1944The effect of infusing glycine and of varying the dietary protein on renal hemodynamics in dog.Am J Physiol142355365Google Scholar
  56. Doolan, Pd, Harper, Ha, Hutchin, Me, Shreeve, Ww 1955Renal clearance of eighteen individual amino acids in human subjects.J Clin Invest3412471255Google Scholar
  57. Doolan, Pd, Harper, Ha, Hutchin, Me, Alpen, El 1956The renal tubular response to amino acid loading.J Clin Invest35888896Google Scholar
  58. Graham, Lt, Shank, Rp, Werman, R, Aprison, Mh 1967Distribution of some synaptic transmiter suspects in cat spinal cord. Glutamic acid, aspartic acid, γ-aminobuturic acid, glycine, and glutamine.J Neurochem14465472Google Scholar
  59. Johnson, Jl, Aprison, Mh 1971The distribution of glutamate and free amino acids in thirteen specific regions of the eat central nervous system.Brain Res26141148Google Scholar
  60. Yatzidis, H 2002A new, superior, single and stable, amino acid and bicarbonate-based, glucose-free solution for peritoneal dialysis.Dialysis and Transplantation31143150Google Scholar
  61. Bolus, N, Cersomino, E, Chisham, F, Abumrad, Nn 1982Physiology importance of glutamine.Metabolism.38(Suppl 1)15Google Scholar
  62. Souba, Ww, Klimberg, U, Plumbey, Da,  et al. 1990The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection.J Surg Res98383391Google Scholar
  63. Smith, R 1990Glutamine metabolism and its physiology importance.IPEN14405445Google Scholar
  64. Perriello, G, Jorde, R, Nurjhan, N,  et al. 1995Estimation of the glucose-alanine-lactate-glutamine cycles in post absorptive man: role of skeletal muscle.Am J Physiol269E-443E-450Google Scholar
  65. Stumvoll, M, Perriello, G, Meyer, C, Cerich, J 1999Role of glutamine in human carbohydrate metabolism in kidney and other tissues.Kidney Int55778792Google Scholar
  66. Nurjhan, N, Bucci, A, Perriello, G,  et al. 1995Clutamine: A major gluconeogenic precursor and vehicle for interorgan carbon transport in man.J Clin Invest95272277Google Scholar
  67. Hankard, Rg, Darmaun, D, Sager, Bk,  et al. 1995Response of glutamine metabolism to exogenous glutamine in humanAm J Physiol269E663E670Google Scholar
  68. Varnier, M, Leese, Gp, Thompson, J, Rennie, Mj 1995Stimulatory effect of glutamine on glycogen accumulation in human skeletal muscle.Am J Physiol269E309E315Google Scholar
  69. Kreider, M, Stumvoll, M, Mever, C,  et al. 1997Steady strate and non steady measurement of plasma glutamine turnover in humans.Am J Physiol272E621E627Google Scholar
  70. Perriello, G, Nurjhan, N, Stumvoll, M,  et al. 1997Regulation of gluconeogenesis by glutamine in normal postabsorptive humans.Am J Physiol272E437E445Google Scholar
  71. Stumvoll, M, Meyer, C, Kreider, M,  et al. 1998Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans.Metabolism4712271232Google Scholar
  72. Lavoinne, A, Baquet, A, Hue, L 1987Stimulation of glucogen synthesis and lipogenesis by glutamine in isolated rat hepatocytes.Biochem J248429437Google Scholar
  73. Cercosimo, E, Williams, P, Hoxworth, B,  et al. 1989Glutamine blocks lipolysis and ketogenesis of fasting.Am J physiol250E248E252Google Scholar
  74. Vu, G, Thompson, Jr 1990The effect of glutamine on protein turnover in chich sceletal muscle in vitro.Biochem J265593598Google Scholar
  75. Garrison R. Lysine, Tryprophan and other amino acids. Copyright 1982 by Keats. Publishing, hie Printed in United States of America, 27 pine street.Google Scholar
  76. Decker, EA, Ivanov, V, Zhu, BJ, Frei, B 2001Inhibition of low- density lipoprotein oxidation by carnosine.J Agric Food Chem49511516Google Scholar
  77. Moncada, S, Palmer, RM, Higgs, EA 1991Nithric oxide: Physiology, pathophysiology, and pharmacology.Pharmacol Rev43109142PubMedGoogle Scholar
  78. Reyes, AA, Karl, IE, Klahr, S 1994Role of arginine in health and in renal diseases.Am J Physiol267F331F346Google Scholar
  79. Rossitch, E, Alexander, E, Black, PM, Cooke, JP 1991L-arginine normalizes endothelium function in cerebral vessels from hypercholesteremic rabbits.J Clin Invest8712951299Google Scholar
  80. Cooke, JP, Singer, AH, Tsao, PS,  et al. 1992Antitherogentic effects of L-arginine in the hypercolesterolemic rabbit.J Clin Invest9011681172PubMedGoogle Scholar
  81. Tsao, PS, McEvoy, LM, Drexler, H,  et al. 1994Enhanced endothelial adhesivess is attenuated by L-arginine.Circulation89231762182Google Scholar
  82. Boger, RH, Bode-Boger, SM, Mugge, A,  et al. 1995Supplementation of hypercholesterolemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores No production.Atherosclerosis117273284CrossRefPubMedGoogle Scholar
  83. Drexler, H, Zeiher, AM, Meinzer, K, Just, H 1991Connection of endothelial dysfaction in coronary microcirculation of hypercholesterolemic patients by L-arginine.Lancet33815461550CrossRefPubMedGoogle Scholar
  84. Boger RH, Bode-Boger SM, Kienke et al. Dietary L-arginine decrease myointimal cell proliferation and vascular monocyte accumulation in cholesterol -fed rappits. Atherosclerosis 998; 136: 67–77.Google Scholar
  85. Bode-Bager, SM, Boger, RH, Kienk, S,  et al. 1998Chronic dietary supplementation with L-arginine inhabits plately aggregation and thromboxane. A synthesis in hypercholesterolemic rabbits in vivo.Cardiovasc Res17756764Google Scholar
  86. Clarkson, P, Adams, MR, Powe, AJ,  et al. 1996Oral L-arginine improves endothelium -dependent dilation in hypercholesterolemic young adult.J Clin Invest9719891994PubMedGoogle Scholar
  87. Tome, LA, Yu, L, deCastro, L,  et al. 1999Beneficial and harmful effects of L-arginine on renal ischaemia.Nephrol Dial Transplant1411391145Google Scholar
  88. Arfeen, S, Goodship, THJ, Kirkwood, A, Ward, MK 1990The nutritional /metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution.Clin Nephrol33192199Google Scholar
  89. Attman, Po, Alaupovic, P, Samuelson, O 1999Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.Kidney Int56(Suppl 71)S14S17Google Scholar
  90. Kerne, Wf 1994Lipid and the kidney.Kidney Int46910920Google Scholar
  91. Samuelsson, O, Attman, Po, Knight-Gibson, C,  et al. 1998Complex apolipoprotein b-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency.J Am Soc Nephrol914821488Google Scholar
  92. Friedman, M, Byers, So, Rosenman, Rh 1957Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion.Proc Soc Exp Biol Med95586588Google Scholar
  93. Armstrong, Ml, Warner, Ed, Connor, We 1970Regression of coronary atheromatosis in monkeys.Circ Res275967Google Scholar
  94. Armstrong, Me, Megan, Mb 1975Arterial fibrous protein in cynomologous monkeys after atherogenic and regression diets.Circ Res36256261Google Scholar
  95. Malinow, Mr 1983Experimental models of atherosclerosis regression.Atherosclerosis48105118Google Scholar
  96. Small, D, Bond, M, Waugh, D,  et al. 1984Physicochemical and histological changes in the arterial wall of monhuman primates during progression and regression of atherosclerosis.J Clin Invest7315901605Google Scholar
  97. Willams, Kj, Werth, Vp, Wolff, Ja 1984Intravesously administered lecithin liposome: A synthetic antiatherogenic lipid particle.Perspect Biol Med27417431Google Scholar
  98. Radimon, Jj, Badimon, L, Fuster, V 1990Regression of atherosclerotic lessions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.J Clin Invest8512341241Google Scholar
  99. Arnezenious, Ac 1991Regression of atherosclerosis benefit can be expected from low LDL-C and high HDL-C levels (Editorial).Acta Cardiologica46431438Google Scholar
  100. Defevier, P, Serruys, P, Davies, M,  et al. 1991Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations and implications for clinicals.Circulation84412423Google Scholar
  101. Oliver, Mf 1992Clinical perspective of trial of regression of coronary atherosclerosis.Cardiovasc Risk Factors2234238Google Scholar
  102. Davies, Mj, Woolf, N 1993Atherosclerosis: What is it and why does it occur?Heart J69(Suppl)S3S1lGoogle Scholar
  103. Brown, Bg, Zhao, Xo, Sacco, De, Albers, Jj 1993Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease.Circulation8717811791Google Scholar
  104. Moncada, S, Martin, Je, Higgs, A 1993Symposium on regression of atherosclerosis.Europ J Clin Invest23385398Google Scholar
  105. Schell, Wd, Myers, Jn 1997Regression of atherosclerosis: a review.Prog. Cardiovasc Dis39483496Google Scholar
  106. Fogo, Ab 2001Progression and potential regression of glomerulosclerosis (Nephrology Forum-Eds: JJ Cohen, JJ Harrington and NE Madias).Kidney Int59804819Google Scholar
  107. Mercer, LP, Dodds, S J, Veber, MD, Dunn, JD 1990Histidine, histamine, and neuroregulation of food intake: a review and hypothesis.Nutrition6273277Google Scholar
  108. Patterson, Ra, Leake, Ds 1998Human serum cysteine and histidine inhibit the oxidation of low density lipoprotein less at acidic pH.FEES Lett434317321Google Scholar
  109. Klebanov, GI, Teselkin, YuO, Balenkova, IV,  et al. 1998Effect of carnosine and its components on free-radical react.Member Cell Biol128999Google Scholar
  110. Peterson, JW, Boldogh, I, Popov, VL,  et al. 1998Anti-inflammatory and antisecretory potential of histidine in salmonella -challenged mouse small intesting.Lap Investig78623534Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  1. 1.Laboratory for Experimental Surgery and Surgical ResearchSchool of Medicine, University of AthensAthens,HellasGreece

Personalised recommendations